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A B S T R A C T
Objectives: A new patient-reported outcome (PRO) instrument to
measure fatigue symptoms and impacts in relapsing multiple scle-
rosis (RMS) was developed in a qualitative stage, followed by psy-
chometric validation and migration from paper to an electronic
format. Methods: Adult patients with relapsing-remitting multiple
sclerosis (RRMS) were interviewed to elicit fatigue-related symptoms
and impacts. A draft questionnaire was debriefed in cognitive in-
terviews with further RRMS patients, and revised. Content confirma-
tion interviews were conducted with patients with progressive-
relapsing multiple sclerosis (PRMS) and relapsing secondary-
progressive multiple sclerosis (RSPMS). Psychometric analyses used
data from adult patients with different RMS subtypes and matched
non-RMS controls in a multicenter, observational study. After item
reduction, the final instrument was migrated to a smartphone (eDiary)
and usability was confirmed in interviews with additional adult RMS
patients. Results: The qualitative stage included 37 RRMS, 5 PRMS, and
5 RSPMS patients. Saturation of concepts was reached during concept
elicitation. Cognitive interviews confirmed that participants under-
stood the instructions, items, and response options of the
instrumentdnamed FSIQ-RMSdas intended. Psychometric validation
included 164 RMS and 74 control patients. Internal consistency and
testeretest reliability were demonstrated. The symptoms domain
discriminated along the RMS symptom-severity continuum and be-
tween patients and controls. Patients were able to attribute fatigue-
related symptoms to RMS. Usability and conceptual equivalence of
the eDiary were confirmed (n ¼ 10 participants). Conclusions: With 7
symptom items and 13 impact items (in 3 impacts subdomains:
physical, cognitive and emotional, and coping) after item reduction,
the FSIQ-RMS is a comprehensive, valid, and reliable measure of
fatigue-related symptoms and impacts in RMS patients.
Keywords: fatigue, patient-reported outcome, relapsing multiple scle-
rosis, symptoms
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Introduction
Fatigue is one of the most common symptoms of multiple scle-
rosis (MS),1e3 a chronic autoimmune disorder of the central ner-
vous system.4 Often described as a feeling of extreme mental or
physical exhaustion, MS-related fatigue has far-reaching effects
on quality of life, employment, and productivity,5e7 imposing
limitations independently of MS-related physical disability and
depression.8
Given the subjective nature of fatigue, the effect of treatment
on fatigue in MS is best assessed via a patient-reported outcome
(PRO) instrument.9 Such a tool would also be valuable in clinical
practice, as MS guidelines and proposed quality-of-care measures
call for fatigue assessment using a PRO instrument with demon-
strated consistency, reliability, and validity.10,11 The 2009 Food
and Drug Administration (FDA) PRO guidance, the FDA's 2015
roadmap to patient-focused outcome measurement in clinical
trials, and the 2015 recommendations from the ISPOR Clinical
Outcomes AssessmentdEmerging Good Practices for Outcomes
Research Task Force all emphasize the need to document the
content and construct validity, reliability, and sensitivity to
change of a PRO instrument.12e14
Although available PRO instruments have been used to
measure fatigue in MS patients,10,15e20 review of their
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measurement properties suggests shortcomings in terms of
current standards for PRO instrument development. For
instance, the 9-item Fatigue Severity Scale (FSS) and the 21-item
Modified Fatigue Impact Scale (MFIS) do not fit the assumption of
unidimensionality, and so studies using their global scores may
need to be reevaluated.21,22
A primary requirement is to develop and validate a PRO in-
strument in the disease-specific target patient population for
intended use. The clinical course of MS broadly falls into re-
lapsing and progressive forms (RMS and PMS, respectively).23
Three RMS subtypes are recognized.23e25 Relapsing-remitting
MS (RRMS), seen in approximately 80% to 85% of MS patients,
is characterized by acute exacerbations with full or partial re-
covery, and patients are generally stable between exacerbations.
Progressive-relapsing MS (PRMS), which afflicts roughly 5% of MS
patients, is marked by progression starting at disease onset, with
occasional relapses. Relapsing secondary-progressive MS
(RSPMS) gradually progresses later (after a median of 20 years) in
the disease course of approximately 65% to 70% of RRMS
patients.
As symptoms and their impacts could differ among these
various forms of MS, a PRO instrument should be validated in the
specific MS subtypes for which it will be used. A unidimensional
version of the FIS (U-FIS) has been developed to address the
multidimensionality of the original 40-item Fatigue Impact Scale
(FIS) and the MFIS,17,26 but some participants in its validation
research were recruited from patient organizations rather than
clinical centers, precluding confirmation of all participants' MS
diagnoses or their type of MS. Some other MS-specific fatigue
questionnaires, such as the FSS,15 were developed in patients with
PMS rather than RMS, which may affect their applicability as
outcome measures in RMS.
Another issue is whether a questionnaire comprehensively
measures MS symptoms and their impact; for example, the FSS
does not include items regarding cognitive fatigue,27 whereas the
FIS and MFIS assess the impact of symptoms on patient func-
tioning, rather than measuring the severity of the symptoms
themselves.2,10,16
The objective of the present research was to address limita-
tions of existing MS-specific instruments by developing a new,
content-valid, concise PRO instrument to assess fatigue symp-
toms relevant to patients within the spectrum of RMS and the
relevant impact of these symptoms on patients' lives, in accor-
dance with the FDA PRO guidance.
Methods
Overview
Development and psychometric validation of the new PRO in-
strument was conducted in 6 research stages, preceded by a
literature review (Fig. 1). Development of the draft questionnaire
was based on qualitative research in patients with RMS, including
concept elicitation and cognitive interviews (n ¼ 17 and 20,
respectively) in patients with RRMS, and content confirmation
interviews in patients with PRMS (n ¼ 5) and RSPMS (n ¼ 5).
Finalization of the new instrument and psychometric validation
analyses were based on data gathered in an observational study, a
real-world cross-sectional study, and a study to confirm the con-
ceptual equivalence and usability of an electronic version of the
questionnaire.
All study-stage protocols were approved by centralized Insti-
tutional Review Boards, and all participants provided written
informed consent. All interviews were conducted by experienced
interviewers trained in the use of semistructured interview guides
specific to each study stage.
Literature Review
Literature reviewswere conducted to identify evidence on fatigue-
related symptoms of RMS and their impacts. Relevant data were
used to inform development of preliminary conceptual frame-
works for RMS symptoms and impacts, which in turn were used to
inform the concept elicitation interview guides. Searches were
conducted in Medline and covered a 10-year period for RRMS-
related searches (January 2000 to September 2010) and for subse-
quent searches pertaining to PRMS and RSPMS (January 2002 to
February 2012).
Qualitative Research
Stage 1: concept elicitation interviews in RRMS
Face-to-face concept elicitation interviews in patients with RRMS
were conducted to identify and describe fatigue-related symp-
toms and impacts from the patient perspective. The FIS was also
cognitively debriefed to determine the extent to which it may
assess RRMS symptoms and impacts and therefore be fit for pur-
pose as an efficacy endpoint measure.
In these concept elicitation interviews, each participant was
asked open-ended questions to spontaneously elicit fatigue-
related symptoms of RRMS and their impacts as experienced by
the participant. Probing questions were posed if the initial open-
ended queries did not elicit an explicit description of a fatigue-
related symptom or impact.
After qualitative analysis of the interview transcripts, concept
saturation was assessed. Saturation was considered to be ach-
ieved at the point at which no new, relevant concepts emerged
from subsequent interviews. A sample size of 15 was anticipated
to be sufficient to achieve saturation.28 Two additional partici-
pants were recruited to account for no-shows or cancellations.
As described in the Results, the FIS would have required too
many modifications to attain content validity in an RRMS popu-
lation. Therefore, a new PRO instrument to assess fatigue-related
symptoms of RRMS and their impacts was drafted by the in-
vestigators based on the concepts spontaneously elicited in in-
terviews. After the preliminary conceptual framework, the
instrument comprised a symptoms domain with a 24-hour recall
period and an impacts domain with a 7-day recall period. Con-
cepts reported by more than 5 (>29.4%) of the 17 participants were
selected for inclusion in the initial paper questionnaire. The new
instrument was named the “Fatigue Symptoms and Impacts
QuestionnairedRelapsing Remitting Multiple Sclerosis” (FSIQ-
RRMS).
Stage 2: cognitive interviews in RRMS
Face-to-face cognitive interviews were conducted to assess the
relevance, comprehensibility, acceptability, and comprehensive-
ness of its items, in addition to the interpretability and appropri-
ateness of instructions, response options, and the recall period of
the FSIQ-RRMS. These cognitive interviews included 20 patients
with RRMS who had not been included in stage 1.
An item was subject to revision if at least 5 (25.0%) of the 20
respondents gave consistent recommendations for its change (eg,
rewording or deletion), demonstrated difficulty interpreting it, or
did not interpret it as intended. The same threshold was applied
for the addition of suggested new items to the questionnaire.
Stage 3: content confirmation interviews in PRMS and RSPMS
After stage 2, it was decided to expand the target population for
the new PRO instrument to encompass a broader range of RMS
patients. One-on-one content confirmation interviews were con-
ducted in patients with PRMS or RSPMS to test the understand-
ability, comprehensiveness, and relevance of the instrument in
these RMS subtypes.
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Concept elicitation and cognitive interviews were conducted
using semistructured interview guides based on preliminary
conceptual frameworks developed for RSPMS and PRMS fatigue-
related symptoms and impacts. Interview findings indicated
that no revisions were required for application of the PRO in-
strument to patients with PRMS and RSPMS. The instrument was
renamed the “Fatigue Symptoms and Impacts Ques-
tionnairedRelapsing Multiple Sclerosis” (FSIQ-RMS).
Psychometric Validation
Stage 4: observational study
Psychometric validation was performed in an observational study
that also included a control group of non-MS patients to demon-
strate the ability of RMS patients to attribute fatigue symptoms to
their disease (n ¼ 164 patients with RMS þ 74 controls).
Psychometric analyses included tests of item response and
dimensionality, Rasch and exploratory factor analyses to assess
content validity, and analyses of construct validity, internal con-
sistency reliability, and testeretest reliability. These analyses
were followed by an attribution analysis and development of a
scoring algorithm. After item reduction, the final version of the
questionnaire underwent confirmatory factor analysis, Rasch
analysis (only conducted on the unidimensional domain; ie,
symptoms), known-groups analysis (only for the symptoms
domain because the focus of the instrument was to be able to
support a PRO labeling claim for symptoms), and assessments of
concurrent and discriminant validity and of internal consistency
and testeretest reliability (for symptoms and impacts domains).
In the 12-week study period, patients with RMS were instruc-
ted to complete the paper version of the FSIQ-RMS at home (apart
from day 1) during 2 intervals: interval 1, from days 1 to 8, where
day 1 was used to collect baseline data on the symptoms and
impacts items, whereas days 2 to 8 were the first full week of
completion of the instrument, and interval 2, from days 80 to 86.
Participants were instructed to complete the symptoms domain
daily and the impacts domain on days 1, 8, and 86.
Additional PRO questionnaires had to be completed at 3 site
visits. Visit 1 occurred on day 1, whereas visits 2 and 3 could occur
within a 3-day window after completion of intervals 1 and 2 to
accommodate participants' scheduling conflicts. Additional in-
struments administered included the Medical Outcomes Study
RAND-3629 at visits 1 and 3, and Patient Global Impression of
Severity (PGI-S) scales30 modified for RMS and fatigue and the
MFIS10 at visits 1, 2, and 3. Clinicians completed the Expanded
Disability Status Scale (EDSS)31 at visit 1, and a Clinician Global
Impression of Change (CGI-C)32 at visits 2 and 3.
Control participants without an MS diagnosis completed an
adaption of the FSIQ-RMS with all references to RMS removed, at
home from days 1 to 7 with a site visit at day 1. Control partici-
pants were patients presenting for an acute condition or a
checkup and were required to meet the eligibility criteria
described in Table 1. Controls were individually matched to RMS
patients by sex, age group (in 10-year age cohorts), and race or
ethnicity.
Stage 5: real-world study in RMS
Originally developed in US English, the FSIQ-RMS was translated
and linguistically validated in 45 language versions (following the
Principles of Good Practice for the Translation and Cultural
Adaptation Process for PRO Measures33), including German. As an
Literature review on RRMS
Preliminary RRMS
conceptual framework
Stage 1: Concept elicitation 
interviews
(RRMS, n = 17)
Draft PRO: FSIQ-RRMS v1
Stage 2: Cognitive interviews 
(RRMS, n = 20)
PRO revision: FSIQ-RRMS v2
Mixed methods analysis
PRO revision: FSIQ-RRMS v3
Stage 3: Content confirmation 
interviews
(PRMS, n = 5; RSPMS, n = 5)
Literature review on PRMS, 
RSPMS
Preliminary PRMS & RSPMS
conceptual frameworks
Stage 4: Psychometric validation 
in observational study
(RRMS, n = 139; PRMS, n = 8; 
RSPMS, n = 18; controls, n = 74)
Item analysis, content confirmation
PRO revision: FSIQ-RMS v2
Reliability/validity analysis,
attribution analysis
Final FSIQ-RMS®
paper version
Stage 6: eDiary migration & 
usability study
(RRMS, n = 8; RSPMS, n = 2)
Revised FSIQ-RMS® eDiary
Future research: 
Responsiveness & meaningful 
change in Phase 3 trials:
OPTIMUM and POINT
Final scoring algorithm Stage 5: Real-world study(RRMS, n = 149; RSPMS, n = 5)
PRO renamed FSIQ-RMS v1
Fig. 1 – Study flow. MS, multiple sclerosis; PRO, patient-reported outcome; PRMS, progressive-relapsing MS; RRMS,
relapsing-remitting MS; RSPMS, relapsing secondary-progressive MS.
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addition to a real-world study conducted in Germany and the
United States, the FSIQ-RMS was administered to provide data for
a supplementary analysis of performance of the symptom items
in a real-world setting (n ¼ 154), and to assess differential item
functioning in MS patients with depression. As the real-world
study was not designed specifically to validate the FSIQ-RMS, it
is reported only briefly here, with further details provided in
Appendix 1 (see Supplemental Materials found at https://doi.org/1
0.1016/j.jval.2018.11.007).
Stage 6: eDiary migration and usability study
The final stage was a qualitative migration and usability study in
patients with RMS in the United States (n ¼ 10) to demonstrate
readability, ease of use, acceptability of an electronic version of
the FSIQ-RMS (“eDiary”), and conceptual equivalence between
paper and electronic platforms (stage 6).
Before testing, minor changes were made to the FSIQ-RMS to
simplify the instructions (these changes were also made to the
Table 1 – Patient eligibility criteria
Study stage Inclusion criteria Exclusion criteria
RMS patients
All stages RMS diagnosis as defined by the revised
McDonald Diagnostic Criteria for MS
Completed written ICF
Ambulatory
Fluent in English
Capable of participating in a 90-minute face-to-
face interview
Any condition that may result in energy- or
fatigue-related symptoms (other than RMS)
Any condition or situation that may interfere
significantly with study participation
Stage 1: Concept elicitation
interviews
Stage 2: Cognitive
interviews
Age 18 years
RRMS diagnosis
At least 1 of the following:
1 documented relapse in the last 12 months
2 documented relapses in the last 24 months
EDSS score of 0 to 5.5 in the past 6 months
Stable course since EDSS assessment
Current treatment for an autoimmune disorder
other than MS
Stage 3: Content confirmation
interviews
Age 18 to 65 years
PRMS or RSPMS diagnosis
EDSS score of 3 to 5.5 in the past 6 months
Documented relapse during prior 12 months
Current treatment for an autoimmune disorder
other than MS
RRMS diagnosis
Stage 4: Psychometric
validation
Age 18 to 65 years
EDSS score of 0 to 5.5 in the past 1 month or at
study entry
Documented relapse during past 12 months,
excluding the month before baseline visit
Medical records available for12months or since
time of RMS diagnosis (if diagnosed during past
12 months)
Current treatment for an autoimmune disorder
other than MS
History of suicidal ideation
Participation in trial with investigational
medications for any condition
Stage 6: eDiary migration &
usability study
Age 18 to 55 years
EDSS score of 0 to 5.5 in the past 3 months
Documented relapse(s): 1 during past 1 year or
2 during past 2 years, excluding the 30 days
before screening
Participation in another research study within
30 days before screening
Previous participation in any study related to the
development of the FSIQ-RMS
Controls
Stage 4: Psychometric
validation
Age 18 to 65 years
Fluent in English
Completed written ICF
Employed as a shift worker
Diagnosis of insomnia, sleep apnea, or any
disease that might cause symptoms of fatigue
Use of any medication that could cause
symptoms of fatigue
Any acute disease that is not cured
Condition that might interfere significantly with
study participation, or predicted to be unable to
comply with protocol
Participation in trial with investigational
medications for any condition
EDSS, Expanded Disability Status Scale; ICF, subject information and consent form including authorization to use and disclose personal health
information for research; MS, multiple sclerosis; PRMS, progressive-relapsing MS; RMS, relapsing MS; RRMS, relapsing-remitting MS; RSPMS,
relapsing secondary-progressive MS.
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paper version), with additional changes to make them appro-
priate for administration on a handheld electronic devicedspe-
cifically, a BLU Life Play Android smartphone. The eDiary
presented the questionnaire in landscape format with 1 item per
screen, providing more room for the horizontal numeric rating
scale and space between the responses to facilitate response
selection for MS patients who may have problems with fine
motor control.
At in-person site visits, participants received training on use of
the eDiary, and completed paper and eDiary versions of the FSIQ-
RMS and a device-usability questionnaire with 6 questions scored
on a verbal rating scale anchored at 1 (“Very easy”) and 5 (“Very
difficult”).
One-on-one cognitive interviews were conducted to probe for
participants' interpretation of questions and response options and
their perspectives on the usability of the eDiary.
Patient Population
Other than the control participants, all participants in all study
stages had RMS diagnoses as defined by the revised McDonald
Diagnostic Criteria for MS,34 with additional subtype diagnostic
criteria for the RRMS, PRMS, and RSPMS patients. Recruitment
aimed to enroll participants generally representative of the RMS
population likely to be enrolled in future clinical trials.
As shown in Table 1, eligibility criteria were highly consistent
acrossstudy stages.Nevertheless, theupper limit of the age range for
eligibility was decreased from 65 years in early study stages to
55 years in later stages to alignwith the inclusion criteria in 2 phase 3
trials of ponesimod in RMS (OPTIMUM ClinicalTrials.gov identifier
NCT02425644 and POINT ClinicalTrials.gov identifier NCT02907177).
Data Analysis
For the qualitative research, participant interviews were audio
recorded, transcribed, and anonymized by a third-party tran-
scription agency for qualitative analysis using ATLAS.ti software
(ATLAS.ti Scientific Software Development GmbH, Berlin, Ger-
many). Initial coding schemes were developed based on the
respective interview guides. Codeswere reviewed andmodified by
the coders as transcripts were analyzed.
In the psychometric validation analyses, item scores were
assessed for floor and ceiling effects (ie, the clustering of item
scores at the top and bottom of the response-scale range,
respectively); a threshold of 9% of respondents in the highest or
lowest response option was applied. Item discrimination was
evaluated using the proportion of participants who endorsed a
score for each symptom item within the range of their overall
score severity across items (categorized as mild ¼ 0 to 3,
moderate ¼ 4 to 6, or severe¼ 7 to 10), with a threshold of 50%. For
inter-item correlation analysis, item pairs with polychoric corre-
lation coefficients of >0.8 were considered to have a high corre-
lation.35 Because the symptoms domain was considered to
measure a unidimensional construct, only symptom items with
inter-item correlations greater than 0.90 were reviewed for po-
tential deletion. In exploratory factor analysis, items with factor
loadings <0.40 on all factors identified were reviewed for possible
deletion.36 Internal consistency reliability was assessed by
calculating the Cronbach's alpha coefficient for each domain and
was considered to be met if the Cronbach's alpha coefficient was
>0.70.37 Evaluation of the item hierarchy and ability of the in-
strument to distinguish between high and low performers used
item and person separation indices and item and person reli-
ability indices, with acceptance thresholds of >2.0 for separation
indices and >0.8 for reliability indices.38 Testeretest reliability was
assessed using the intraclass correlation coefficient (ICC), calcu-
lated using ShrouteFleiss reliability for a single score, with an ICC
of 0.70 considered to be acceptable.39 Unidimensionality was
considered to have been demonstrated if >60% of variance was
explained by the Rasch factor and <5% was explained by the first
residual factor.40 Sufficient concurrent validity between the new
PRO instrument and other instruments was considered if the
correlation coefficient was 0.4 to 0.7.41,42 Descriptive statistical
analysis of data for the psychometric analyses was performed
using SAS (SAS Institute Inc., Cary, NC, USA). Rasch analyses were
performedwithWinsteps (Linacre JM, Beaverton, OR, USA. https://
www.winsteps.com/winman/references.htm).
Quantitative results are reported as counts and percentages for
discrete variables and mean ± standard deviation (SD) for
continuous variables.
Results
Participant Characteristics
Characteristics of the participants are reported in Table 2. Across
the study stages, participants were predominantly female with
mild-to-moderate disease severity, and diverse in age, race/
ethnicity, work status (see Appendix 2 in the Supplemental
Materials found at https://doi.org/10.1016/j.jval.2018.11.007 for
additional employment details), and educational attainment.
Stage 1: Concept Elicitation Interviews in RRMS
Concept elicitation interviews were conducted with a total of 17
participants at 3 US sites in November 2010, and analyses
demonstrated that saturation was achieved.
The most commonly reported fatigue-related symptoms were
energy and weakness. Functional and emotional impacts of
fatigue-related symptoms were reported, including difficulty
walking, maintaining relationships, participating in social activ-
ities, and performing general activities of daily living, as well as
difficulty with thought processes. Elicited symptom and impact
concepts are reported in Table 3.
Based on the cognitive debriefing of the FIS, it was determined
that this instrument does not sufficiently measure fatigue-related
symptoms and their impacts on the RRMS population. The FIS is
primarily an impact instrument. Furthermore, most concepts
represented in the FIS were reported infrequently or not at all by
participants; conversely, several concepts elicited were not pre-
sent in the FIS.
Based on the results of the concept elicitation interviews and
applying the above-mentioned criteria to generate items, a draft
version of the new PRO instrument was developed. Instrument
drafting also took into account evidence from the literature review
and input from clinical experts experienced in treating patients
with MS. Reasons for including or not including elicited concepts
in the draft instrument are presented in Table 3. Named the “FSIQ-
RRMS,” the questionnaire comprised 30 items across 2 hypothe-
sized domains: fatigue-related symptoms (n ¼ 16) and impacts of
fatigue-related symptoms (n ¼ 14).
Symptom items use an 11-point numeric rating scale assessing
the severity of each item, with response options ranging from
“Not at all” (0) to “Extremely” (10). This response scale was
selected as it is commonly used in clinical settings to assess
symptom severity. A recall period of “the past 24 hours” was
chosen because symptoms may vary between days.
Impact items use a 5-point verbal rating scale to assess the
severity or frequency of each impact, with response options
ranging from “No difficulty” to “Extreme difficulty,” “Not at all” to
“Extremely,” or “Never” to “Almost all of the time.” A numeric
rating scale was not considered appropriate for impacts because
items in the impact domain of the questionnaire assess different
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aspects of the patient experience (eg, severity and frequency), and
so including verbal prompts for each response choice in the rating
scale was considered to be important. A 5-point scale was selected
to allow sensitivity in the response choices without adding too
much complexity for the patients.43 A recall period of “past 7 days”
was used for all impact items because impacts may not be expe-
rienced during each day of a 1-week evaluation period.
Stage 2: Cognitive Interviews in RRMS
Cognitive interviews were conducted with an additional 20 RRMS
patients at 3 US sites in February 2011. Overall, the participants
reported the draft FSIQ-RRMS instrument to be comprehensive,
understandable, and relevant. Nevertheless, participants had a few
comments, which were addressed by modifications to the draft
questionnairednamely, removal of 8 symptom items that partici-
pants did not interpret as intended (all 6 “at rest” items,whichwere
commonly misinterpreted, and both “exhausted” items, as
“exhausted” overlappedwith other concepts andwas considered by
most participants to be a more severe sensation of “tiredness”),
revision of the item stem for 6 symptom items to specify that the
fatigue symptoms were attributable to RRMS, revision of the item
stem for all impact items to specify that the impacts experienced
were attributable to fatigue, and rewording of 2 impact items to be
Table 2 – Patient demographic and clinical characteristics
Characteristic Stage 1:
Concept
elicitation
(N ¼ 17)
Stage 2:
Cognitive
interviews
(N ¼ 20)
Stage 3: Content
confirmation
Stage 4: Psychometric
validation
Stage 6: eDiary
migration &
usability
study (N ¼ 10)PRMS
(N ¼ 5)
RSPMS
(N ¼ 5)
RMS patients
(N ¼ 164)
Controls
(N ¼ 74)
RMS subtype, n (%)
RRMS 17 (100) 20 (100) e e 139 (84) NA 8 (80)
RSPMS e e e 5 (100) 18 (11) NA 2 (20)
PRMS e e 5 (100) e 8 (5) NA 0
Age, years, mean ± SD
(range)
43.9 ± 13.3
(27 to 75)
47.0 ± 12.0
(25 to 69)
52.6 ± 12.5
(34 to 67)
52.4 ± 10.8
(38 to 63)
45 ± NA
(19 to 65)
40 ± NA
(18 to 65)
42.1 ± 8.2
(27 to 54)
Female, n (%) 13 (76) 16 (80) 4 (80) 3 (60) 124 (76) 54 (73) 7 (70)
Race/ethnicity, n (%)
Caucasian/white 13 (76) 17 (85) 2 (40) 4 (80) 133 (81) 56 (76) 5 (50)
African American/
African Caribbean/
Black
2 (12) 3 (15) 3 (60) 1 (20) NA NA 4 (40)
Hispanic 0 0 0 0 NA NA 1 (10)
Asian 1 (6) 0 0 0 NA NA 1 (10)
American Indian or
Alaskan Native
1 (6) 0 0 0 NA NA 1 (10)
Work status, n (%)*
Working/studying 8 (47) 8 (40) 2 (40) 0 NA NA 5 (50)
Not working 9 (53) 12 (60) 3 (60) 5 (100) NA NA 5 (50)
Highest level of
education, n (%)
High school diploma
or GED
1 (6) 2 (10) 0 1 (20) 47 (29) 13 (18) 2 (20)
Some college or
certificate program
4 (24) 8 (40) 2 (40) 2 (40) 50 (30) 26 (35) 4 (40)
College or university
degree
12 (71) 10 (50) 3 (60) 2 (40) 66 (40) 34 (46) 4 (40)
Other 1 (1) 1 (1) 0
MS severityy
Very mild 1 (6) 4 (20) 0 0 e NA 0
Mild 7 (41) 7 (35) 1 (20) 2 (40) 92 (56) 3 (30)
Moderate 9 (53) 9 (45) 4 (80) 2 (40) 58 (35) 7 (70)
Severe 0 0 0 1 (20) 14 (9) 0
EDSS score, n (%)
0.0 to 1.0 4 (24) 4 (20) e e 23 (14) NA 1 (10)
1.5 to 2.0 2 (12) 4 (20) e e 36 (22) 3 (30)
2.5 to 3.0 4 (24) 4 (20) 0 0 36 (22) 1 (10)
3.5 to 4.0 5 (29) 6 (30) 3 (60) 1 (20) 37 (23) 1 (10)
4.5 to 5.0 1 (6) 0 2 (40) 0 32 (20) 3 (30)
5.5 to 6.0 1 (6) 2 (10) 0 4 (80) 1 (10)
EDSS, Expanded Disability Status Scale; MS, multiple sclerosis; NA, not available; PRMS, progressive-relapsing MS; RMS, relapsing MS;
RRMS, relapsing-remitting MS; RSPMS, relapsing secondary-progressive MS.
* Employment details are reported in Appendix 2 in the Supplemental Materials found at https://doi.org/10.1016/j.jval.2018.11.007.
y As assessed by patient for stages 1 to 3, 6: “Very mild,” “Mild,” “Moderate,” or “Severe;” as assessed by PGI-S MS score for stage 4: Mild ¼ 0 to 3,
Moderate ¼ 4 to 6, Severe ¼ 7 to 10.
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Table 3 – Elicited fatigue-related symptom and impact concepts reported by participants
Concept Frequency,
n (%)
Preliminary
decision
Rationale
Symptoms
Tiredness 15 (88.2) Exclude  Instrument will include items specific to physical and mental tiredness.
 Concept is not mutually exclusive with “physical” and “mental” tiredness.
Physical tiredness 12 (70.6) Include  Concept was frequently reported by participants.
 Item divided into 2 separate questions to distinguish between the severity
of the symptom “while doing routine daily activities” and “while at rest.”
Mental tiredness 6 (35.3) Include  Concept was somewhat frequently reported by participants.
 Item does not differentiate between “while doing routine daily activities”
and “while at rest” as this is not a physical concept.
Fatigue 11 (64.7) Exclude  Instrument will include items specific to physical and mental fatigue.
 Concept is not mutually exclusive with “physical” and “mental” fatigue.
Physical fatigue 7 (41.2) Include  Concept was somewhat frequently reported by participants
 Item divided into 2 separate questions to distinguish between the severity
of the symptom “while doing routine daily activities” and “while at rest.”
Mental fatigue 6 (35.3) Include  Concept was somewhat frequently reported by participants
 Item does not differentiate between “while doing routine daily activities”
and “while at rest” as this is not a physical concept.
Weakness 10 (58.8) Include  Concept was somewhat frequently reported by participants.
 Concept was solely reported as a physical concept by participants (ie, par-
ticipants did not report weakness as a mental concept).
 Item divided into 2 separate questions to distinguish between the severity
of the symptom “while doing routine daily activities” and “while at rest.”
Exhaustion 9 (52.9) Exclude  Instrument will include items specific to physical and mental exhaustion.
 Concept is notmutually exclusive with “physical” and “mental” exhaustion.
Physical exhaustion 6 (35.3) Include  Concept was somewhat frequently reported by participants.
 Item divided into 2 separate questions to distinguish between the severity
of the symptom “while doing routine daily activities” and “while at rest.”
Mental exhaustion 6 (35.3) Include  Concept was somewhat frequently reported by participants.
 Item does not differentiate between “while doing routine daily activities”
and “while at rest” as this is not a physical concept.
Low energy 7 (41.2) Include  Concept was somewhat frequently reported by participants.
 Participants primarily discussed the physical impacts of energy when
defining the concept.
 Participants typically discussed energy as an amount (depleted, low, or
burst of energy).
Worn out/wiped out/run
down
6 (35.3) Include  Concept was somewhat frequently reported by participants.
 Participants used different words to describe this concept; however, “worn
out” was most frequently reported (n ¼ 5).
 These terms were used to describe both physical and mental concepts;
therefore, no further differentiation done.
Sleepiness/Grogginess/
Drowsiness
5 (29.4) Include  Concept was somewhat frequently reported by participants.
 The term “sleepy” was reported by 3 participants; 1 participant each re-
ported “grogginess” or “drowsiness.”
Drained 4 (23.5) Exclude  Concept was infrequently reported by participants.
 Concept was inconsistently defined by participants.
Heaviness (physical
heaviness in limbs)
3 (17.6) Exclude  Concept was infrequently reported by participants.
 Reports of heaviness were specific to areas of the body that were different
for participants (eg, arms, legs, and head were all reported).
Sluggish 2 (11.8) Exclude  Concept was infrequently reported by participants.
Decrease in stamina 1 (5.9) Exclude  Concept was infrequently reported by participants.
Walking 11 (64.7) Include  Frequently reported
Resting/taking breaks 9 (52.9) Include  Concept was somewhat frequently reported by participants.
Having to lay down 8 (47.1) Exclude  Concept covered by “taking breaks”
Having to sit down 6 (35.3) Exclude  Concept covered by “taking breaks”
Unable to do anything/
function physically
6 (35.3) Exclude  General concept of being unable to do anything or function physically is too
broad to be an appropriate item.
Exercising 5 (29.4) Exclude  Concept overlaps with “walking” for 3 out of 5 participants who reference
this as an impact.
 Concept is not a common experience, as not all patients exercise.
Difficulty standing 3 (17.6) Exclude  Concept was infrequently reported by participants.
Lifting 3 (17.6) Exclude  Concept was infrequently reported by participants.
continued on next page
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Table 3 – continued
Concept Frequency,
n (%)
Preliminary
decision
Rationale
Need to push oneself 3 (17.6) Exclude  Concept was infrequently reported by participants.
Slowed movements 3 (17.6) Exclude  Concept was infrequently reported by participants.
Going up/down steps/stairs 2 (11.8) Exclude  Concept was infrequently reported by participants.
Carrying 1 (5.9) Exclude  Concept was infrequently reported by participants.
Falling 1 (5.9) Exclude  Concept was infrequently reported by participants.
Getting in/out of the car 1 (5.9) Exclude  Concept was infrequently reported by participants.
Relationships 10 (58.8) Include  Concept was somewhat frequently reported by participants.
 Participants reported different relationships being impacted, including
parent or child (n ¼ 6, 35.3%), with family (n ¼ 3, 17.6%) or social life (n ¼ 3,
17.6%) in general, husband or wife (n ¼ 2), with relation to dating (n ¼ 2,
11.8%), and boy or girlfriend (n ¼ 1, 5.9%).
Social activities 10 (58.8) Include  Concept was somewhat frequently reported by participants.
 Participants reported a variety of activities, including some that overlap
with leisure activities (eg, bowling, dancing, eating out, going to themovies),
outdoor activities (eg, going to the zoo with family), and socializing in
general (eg, speech).
Planning 5 (29.4) Exclude  Concept overlaps with “rearranging plans.” The concept as it is presented
here is a social concept, but can pertain to general activities of daily living as
well.
Difficulty talking with
others
3 (17.6) Exclude  Concept was infrequently reported by participants.
 Concept overlaps with “communicating clearly.”
General social impact 2 (11.8) Exclude  Concept was infrequently reported by participants.
 Participants were nonspecific in their discussion of social impacts with
these specific quotes.
 Both participants who referenced a social impact with these quotes also
reported impacts on specific social activities, and 1 subject each also re-
ported an impact on social relationships and daily planning, and so there is
potential overlap with other items measuring “social” concepts (eg, social
activities, social relationships, rearranging plans).
Napping 10 (58.8) Include  Concept was frequently reported by participants.
Going to bed early 4 (23.5) Exclude  Concept was infrequently reported by participants.
Difficulty falling asleep 1 (5.9) Exclude  Concept was infrequently reported by participants.
Staying in bed 1 (5.9) Exclude  Concept was infrequently reported by participants.
Errands 8 (47.1) Include  Concept was somewhat frequently reported by participants.
 Participants reported an impact of fatigue-related symptoms on grocery
shopping (n ¼ 5, 29.4%), shopping in general (n ¼ 4, 23.5%), and running
errands (n ¼ 1, 5.9%).
 Item worded to include “running errands” to capture all activities pertinent
to the concept, such as “grocery shopping” and “shopping.” While “going to
the bank or ATM” was not referenced by participants, it is a common
experience.
Driving 7 (41.2) Exclude  Concept is not a common experience, as not all patients drive a vehicle.
General ADL 7 (41.2) Exclude  General concept of ADLs is too broad to be accepted as an appropriate item.
Daily planning 5 (29.4) Include  Concept was somewhat frequently reported by participants.
 All 5 participants referred to having to plan their day around the severity of
their symptoms. Participants mentioned having to “manage” (n ¼ 1),
“negotiate” (n ¼ 1), and “rearrange” (n ¼ 1) plans. “Rearrange” was selected
as it was a specific impact related to planning, that would also cover the
other terms.
Travel 1 (5.9) Exclude  Concept was infrequently reported by participants.
 Concept is not a common experience, as not all patients travel.
Indoor household
activities
8 (47.1) Include  Concept was somewhat frequently reported by participants.
 Participants reported difficulty performing a variety of activities (eg,
washing clothes, ironing, cooking, vacuuming).
 Given that there was no consistency over the range of activities reported, no
examples were provided.
Outdoor household
activities
1 (5.9) Exclude  Concept was infrequently reported by participants.
continued on next page
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Table 3 – continued
Concept Frequency,
n (%)
Preliminary
decision
Rationale
Speech 7 (41.2) Include  Concept was somewhat frequently reported by participants.
 Participants reported several concepts with regard to speech (eg, slurred/
slowed speech, blurting out words, talking gibberish) that all speak to dif-
ficulty articulating thoughts.
 “Communicating clearly” selected as wording to capture all areas of speech
that may be affected.
Thought process 7 (41.2) Include  Concept was somewhat frequently reported by participants.
 While the majority of participants referred to difficulty with their thought
“process” or “processing” information (n¼ 4), “thinking clearly” (n¼ 1) along
with other concepts were reported; “thinking clearly” was selected to
simplify the item while making the concept more specific.
Memory 5 (29.4) Include  Concept was somewhat frequently reported by participants.
 Four participants (80.0%) used the word “forget” when reporting the
concept.
Concentration 4 (23.5) Exclude  Concept was infrequently reported by participants.
 One participant indicated that the difficulty with concentration may have
been caused by impaired vision resulting from MS, not fatigue-related
symptoms brought on by MS.
Reading 4 (23.5) Exclude  Concept was infrequently reported by participants.
Feel less alert 1 (5.9) Exclude  Concept was infrequently reported by participants.
Mentally wiped out 1 (5.9) Exclude  Concept was infrequently reported by participants.
 Nonspecific concept
Frustrated/aggravated/
irritated
5 (29.4) Include  Concept was somewhat frequently reported by participants.
 Feeling “frustrated” was reported most often by participants (n ¼ 3, 17.6%).
Motivation 5 (29.4) Include  Concept was somewhat frequently reported by participants.
Anxious/worried/nervous 4 (23.5) Exclude  Concept was infrequently reported by participants.
 “Anxiety” is a multifaceted term as it contains medical jargon and is also a
medical condition.
Feel bad/lousy/miserable 4 (23.5) Exclude  Concept was infrequently reported by participants.
 General concept of feeling bad is too broad to be accepted as an appropriate
item.
Overwhelmed 4 (23.5) Exclude  Concept was infrequently reported by participants.
Scared 4 (23.5) Exclude  Concept was infrequently reported by participants.
Angry 3 (17.6) Exclude  Concept was infrequently reported by participants.
Depressed 2 (11.8) Exclude  Concept was infrequently reported by participants.
 Concept of “depression” is a multifaceted term, as it is also a medical
condition.
Embarrassed 2 (11.8) Exclude  Concept was infrequently reported by participants.
Feel sorry for self 2 (11.8) Exclude  Concept was infrequently reported by participants.
Disappointed 1 (5.9) Exclude  Concept was infrequently reported by participants.
Feel like a burden 1 (5.9) Exclude  Concept was infrequently reported by participants.
Lack of interest 1 (5.9) Exclude  Concept was infrequently reported by participants.
Overly emotional 1 (5.9) Exclude  Concept was infrequently reported by participants.
Sad 1 (5.9) Exclude  Concept was infrequently reported by participants.
Bathing/washing 5 (29.4) Include  Concept was somewhat frequently reported by participants.
Productivity 5 (29.4) Exclude  Concept is not a common experience, as not all patients with MS are
working.
Schedule 5 (29.4) Exclude  Concept is not a common experience, as not all patients with MS are
working or going to school.
 Overlaps with “rearranging plans”
General work/school
impact
4 (23.5) Exclude  Concept was infrequently reported by participants.
 Concept is not a common experience, as not all patients with MS are
working.
 General concept of work or school is too broad to be accepted as an
appropriate item.
Not working 4 (23.5) Exclude  Concept was infrequently reported by participants.
 Concept is not a common experience, as only some patients with MS are
working.
continued on next page
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more specific. No revisions were required to the recall period or
response options. After revision, the PRO instrument comprised 22
items: 8 fatigue-related symptoms and 14 impacts.
Subsequently, a Rasch analysis was conducted on the partici-
pant responses collected during the stage 2 cognitive interviews.
Based on this analysis, a previously deleted symptom item was
added back to the instrument to ensure that symptoms relevant
for the severe spectrum of the disease were adequately covered,
resulting in 23 items in total.
Stage 3: Content Confirmation Interviews in PRMS, RSPMS
A total of 10 patients with PRMS (n ¼ 5) or RSPMS (n ¼ 5) were
interviewed at 2 US sites in May 2012. In the concept elicitation
portion, new concepts were reported by only 1 or 2 participants,
overlapped with already-included concepts, or were too nonspe-
cific for inclusion in the questionnaire (eg, unable to do anything/
function physically, being in a “bad mood”). Consequently, no
items were added (nor were any other modifications made) to the
draft 23-item questionnaire, which was renamed the “FSIQ-RMS
v1.”
Stage 4: Psychometric Validation in Observational Study
Results of the psychometric analyses are summarized in Table 4.
In total, data were analyzed for 164 patients with RMS recruited
from 15US sites and 74 controls recruited from 3US sites, between
September 2012 and October 2013.
Instrument completion
Only 3 participants had 1 or more missing responses on symptom
items by day 8, and no symptom item had data missing frommore
than 1 participant, indicating thatmissing data are a randomeffect.
The FSIQ-RMS impact items also had low levels of missing data.
Item performance analysis
Participants used the full range of the symptoms scale (0 to 10) and
the impacts scale (0 to 4), with similar distributions for all items.
Substantial ceiling effects were observed for most symptom and
impact items, reflecting the mild-to-moderate patient population
with few ambulatory limitations. Symptom items without ceiling
effects on day 1 and/or day 8 were “Physically tired,” “Physically
fatigued,” and “Energy doing routine daily activities.” The only
impact item without ceiling effects on visit 2 (day 9 to 11) was,
“How often did you have to take a break?”
High pairwise inter-item correlations (0.94) on days 1 and 8,
potentially indicating redundancy between content-related item
pairs, were observed for the symptom items “Mentally tired” and
“Mentally fatigued” and for “Physically tired” and “Physically
fatigued.”No impact item pairs had correlations >0.8 on both days
1 and 8.
The proportion of participants who endorsed a score for each
symptom item within the range of their overall score severity
across items was consistently above the 50% threshold, indicating
that the instrument is able to discriminate between mild, mod-
erate, and severe fatigue.
Factor analysis
In exploratory factor analysis of the 9-item symptoms domain, 1
factor explained 93.4% of the variance (Eigenvalue ¼ 47.74;
P < .0001), supporting the hypothesis that the symptom items
reflect a single underlying construct. Exploratory factor analysis of
the 14-item impacts domain resulted in 3 factors explaining
9.68%, 8.37%, and 4.94% of the variance, respectively
Table 3 – continued
Concept Frequency,
n (%)
Preliminary
decision
Rationale
Attendance 2 (11.8) Exclude  Concept was infrequently reported by participants.
 Concept is not a common experience, as not all patients with MS are
working.
 Overlaps with “rearranging plans”
Relationships with
coworkers
2 (11.8) Exclude  Concept was infrequently reported by participants.
 Concept is not a common experience, as not all patients with MS are
working.
School 2 (11.8) Exclude  Concept was infrequently reported by participants.
 Concept is not a common experience, as not all patients with MS are in
school.
Job security 1 (5.9) Exclude  Concept was infrequently reported by participants.
 Concept is not a common experience, as not all patients with MS are
working.
 Broad concept that would be a secondary impact to other affected areas of
work (ie, fatigue-related symptoms of RRMS would not directly impact job
security; impact of fatigue-related symptoms of RRMS on productivity,
schedule, relationships with coworkers, etc, would impact job security).
Active leisure activities 4 (23.5) Exclude  Concept was infrequently reported by participants.
Sedentary leisure
activities
3 (17.6) Exclude  Concept was infrequently reported by participants.
Sex life 2 (11.8) Exclude  Concept was infrequently reported by participants.
 Concept is not a common experience, as not all patients are sexually active.
Restless legs 1 (5.9) Exclude  Concept was infrequently reported by participants.
Sitting 1 (5.9) Exclude  Concept was infrequently reported by participants.
Financial impact 3 (17.6) Exclude  Concept was infrequently reported by participants.
ADL, activities of daily living; MS, multiple sclerosis; RRMS, relapsing-remitting MS.
Frequently reported, 11 participants; somewhat frequently reported, 5 to 10 participants; infrequently reported, 4 participants.
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Table 4 – Measurement properties of the new PRO in the psychometric study.
Parameter Threshold for
acceptability
FSIQ-RMS
symptoms
domain (9-item),
observational
study, day 1
(N ¼ 164)
FSIQ-RMS
symptoms domain
(7-item),
observational
study, day 1
(N ¼ 164)
FSIQ-RMS
impacts domain
(14-item),
observational
study, day 1
(N ¼ 164)
FSIQ-RMS
impacts domain
(13-item),
observational
study, day 1
(N ¼ 164)
Rasch analysis
Person reliability 0.8 0.93 0.91 0.91 e
Person separation 2.0 3.57 3.19 3.12 e
Item reliability 0.8 0.90 0.92 0.98 e
Item separation 2.0 3.07 3.49 6.32 e
Dimensionality, % 60 76.3 75.0 59.4 e
Item misfit 0.5 to 1.5 No item misfit by day 8.
Slight misfit for the
item “worn out at rest”
on day 1
No item misfit No item misfit e
Residual
correlations
0.40 Mentally tired and
mentally fatigued
(0.66)
Physically tired and
physically fatigued
(0.52)
No residual
correlations
No residual
correlations
e
Measure range 0.21 to 0.38 0.20 to 0.37 1.26 to 1.78 e
Rating scale No disordered steps
between adjacent
categories
No disordered steps
between adjacent
categories
No disordered
steps between
adjacent categories
e
Classical statistics
Item response and
dimensionality
analysis
Complete data 98.2% Evaluated in
Stage 1 to make
item deletion
decisions. Not
evaluated on the
final measure as
the results would
be the same.
e
Ceiling range 9% 3.7% to 16.5% e
Floor range 9% 1.8% to 9.8% e
Inter-item
correlations
0.90 Mentally tired and
mentally fatigued
(0.95)
Physically tired and
physically fatigued
(0.95)
None
Item
discrimination
50% 52% to 60% e
Factor analysis,
explained
variance
40% 93.4%
(Eigenvalue ¼
47.74)
9.68%, 8.37%,
and 4.94%
(Eigenvalue ¼
19.92, 1.88, and
1.18, respectively)
Psychometric
testing of
final
questionnaire
(reliability)
Internal
consistency
reliability
0.7 0.949 Physical: 0.869
Cognitive/
Emotional: 0.879
Coping: 0.872
Testeretest
reliability
0.7 0.928 Physical: 0.946
Cognitive/
Emotional: 0.917
Coping: 0.945
Known-groups
validity
P < .05 for
difference in
scores between
known groups
Significant
difference in
mean scores:
Patients: 44.63
Healthy subjects: 17.67
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(Eigenvalue ¼ 19.92, 1.88, and 1.18, respectively; P < .0001), sug-
gesting that the impact items can be categorized into 3 conceptual
subdomains.
Rasch analysis of the 9-item symptoms domain revealed that a
unidimensional factor explaining most of the variance was “fa-
tigue.” Rasch analysis of the 14-item impacts domain provided
evidence of multidimensionality, with the Rasch dimension
explaining 59.4% and 58.4% of the variance on days 1 and 8,
respectively, thus not reaching the threshold for demonstrating
unidimensionality.
Item reduction
Based on the observed redundancy between symptom items
measuring “fatigue” and “tired,” the items “Physically fatigued”
and “Mentally fatigued” were deleted.
The impacts item related to showering was deleted because it
had a substantial ceiling effect, with 57.9% of participants
responding that they had no difficulty showering. There was also
categorical disordering within the scale, indicating that patients
do not use the response options as intended. In addition, this item
may not be generally applicable in a multinational study because
showers may not be available in all countries.
As a result of these modifications, the final FSIQ-RMS v2
incorporated 1 hypothesized fatigue-related symptoms domain
comprising 7 items, and 3 hypothesized impacts sub-
domainsdphysical, cognitive/emotional, and coping (which is
combinedwith 2 physical impacts subdomain items)dcomprising
13 items (Fig. 2).
Scoring algorithm
A scoring algorithm was developed to standardize scores on both
the symptoms domain (daily and weekly) and impacts sub-
domains (weekly) to a 0 to 100 scale, with higher scores indicating
more severe symptoms and impacts. There is no single summary
score across the FSIQ-RMS instrument, but rather 1 symptoms
score and 3 impacts subdomain scores.
For the average weekly symptoms domain score to be
computed, data from at least 4 daily diaries with at least 4 items
(ie, 50% nonmissing item responses) completed on each day are
needed. If fewer than 4 items are reported on a day, the day is
considered missing. If fewer than 4 days are available within the
7-day period, the observation for the weekly average score is
considered missing.
For the impacts domain, the 2 items present in both the
physical and coping subdomains (“taking part in social activities”
and “rearranging plans”) are multidimensional, and represent
coping strategies related to the physical impact of the disease. For
each impacts subdomain, at least 3 items (ie, 50% nonmissing
item responses) are needed to calculate the respective weekly
subdomain score. If fewer than 3 items are reported, the obser-
vation for that week is considered missing.
Psychometric testing of final FSIQ-RMS
In confirmatory factor and Rasch analyses, the final FSIQ-RMS 7-
item symptoms domain demonstrated unidimensionality, with
the model explaining 75.0% of the variance on day 1 and 83.2% on
day 8. The symptoms domain was shown to contain independent,
reliable items, with item reliability indices ranging from 0.92 to
0.95 across items, exceeding the threshold for demonstrating
score repeatability. Item scores were able to discriminate patients
along the severity continuum, with item separation indices
ranging from 3.49 to 4.35, exceeding the threshold for demon-
strating sensitivity of the instrument.
In analyses of concurrent validity, a higher FSIQ-RMS symp-
toms score wasdas expecteddassociated with lower perceived
health asmeasured by the RAND-36 Energy/fatigue scale on day 1,
and higher fatigue symptoms as measured by the MFIS Physical
subscale on days 1 and 2 to 8 (Table 4). All 3 impacts subdomains
were significantly correlated with the RAND-36 Role functioning/
physical scale on day 1, and the MFIS Physical and Psychosocial
subscales on days 1 and 8.
Known-groups validity was demonstrated by symptoms
domain scores differing significantly between RMS patients and
controls (Table 4).
All symptoms and impacts subdomains of the FSIQ-RMS
exceeded the threshold for internal consistency, with Cron-
bach's alpha on day 1 ranging from 0.869 to 0.949. All symptoms
and impacts subdomains also exceeded the threshold for
demonstrating testeretest reliability, with ICCs ranging from
0.917 to 0.946.
Attribution analysis
The differential item functioning analysis, which was performed
on the symptoms domain, found greater impairment on 3 items in
patients with RMS compared with controls, confirming signifi-
cantly worse fatigue in RMS patients compared with non-RMS
individuals.
In a regression model controlling for age, cognition, and level
of depression, there was a significant 14-point difference in
symptoms score (scale range 0 to 100) between RMS patients and
controls (P < .0001), demonstrating that the fatigue-related
symptoms were attributable to RMS.
Stage 5: Real-World Study
Of 1597 MS patients for whom data were gathered in 2012, 154
completed the FSIQ-RMS symptoms measure and met the eligi-
bility criteria for analysis. Results confirmed that the FSIQ-RMS
symptoms domain items met the unidimensionality and local
Fatigue-related Impacts of RMS
Physical Impacts
• Indoor household chores
• Rearranging plans
• Running errands
• Social activities
• Walking
Cognitive and Emotional Impacts
• Communicating clearly
• Forgetful
• Frustrated
• Maintaining relationships
• Thinking clearly
Coping Impacts
• Motivation
• Napping
• Rearranging plans*
• Social activities*
• Taking a break
Fatigue-related Symptoms of RMS
Fatigue
• Energy
• Mentally tired
• Physically tired
• Physically weak
• Sleepy
• Worn out: activities
• Worn out: at rest
Fig. 2 – Conceptual framework. RMS, relapsing multiple
sclerosis. *Items also present in physical impacts
subdomain.
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independence assumptions of the Rasch model, and supported
the item reductions described above (see Appendix 1 in the
Supplementary Materials found at https://doi.org/10.1016/j.jval.2
018.11.007 for further details).
Stage 6: eDiary Migration and Usability Study
Data were analyzed for a total of 10 participants from 2 US sites
who were interviewed in January 2015. On the device-usability
questionnaire, all participants reported that it was easy or very
easy to learn, use, navigate, read, and see the response choices of
the eDiary.
In interviews, 7 participants (70%) spontaneously reported
preferring the eDiary to the paper format, based on better ease of
use (n ¼ 4), less information per page (n ¼ 2), being quicker and
simpler to use (n ¼ 3), not having to write (n ¼ 1), and providing
better flow (n ¼ 1). Participants generally interpreted the ques-
tionnaire the same way on the 2 platforms.
In the cognitive interviews, participants confirmed that the
symptoms and impacts listed on the FSIQ-RMS were relevant to
their experience with RMS. Participants generally reported un-
derstanding the meaning of the questions, instructions, and
response options, though 2 participants mentioned confusion
about the meaning of “at rest” in 1 question. After stage 6, ex-
amples were added to this question: “eg, reading a book, watching
TV.”
Discussion
Because fatigue is the most frequent symptom of MS and has a
severe impact on patients' health-related quality of life, accu-
rate measurement of fatigue is important in devising the best
treatment strategies for each patient.44 The final FSIQ-RMS is a
valid and reliable PRO instrument that has demonstrated con-
tent and measurement validity for fatigue-related symptom
and impact items. The multistage development and psycho-
metric validation program established that the new question-
naire measures important aspects of fatigue symptoms
attributable to relapsing forms of MS and the impacts resulting
from these symptoms.
Development and validation of the FSIQ-RMS were designed
from the outset to be rigorous with respect to current re-
quirements for PRO instrument development. Recently, other PRO
instruments for assessing fatigue in patients with MS have been
developed following different approaches; for example, the
Neurological Fatigue Index (NFI-MS) comprises a 10-item sum-
mary scale, and scales measuring the physical and cognitive as-
pects of fatigue.19 In contrast to the FSIQ-RMS, the NFI-MS is based
on a fatigue-symptom framework.45
Although the FSIQ-RMS has several strengths, including
rigorous development following the FDA PRO guidance,12
incorporation of the input of RMS patients, and psychometric
validation performed in a stand-alone study that included
controls to confirm attribution of symptoms to RMS, the in-
strument development also has limitations. Because of the
mild-to-moderate disease of most participants, the validity of
the FSIQ-RMS in patients with more severe disease (ie, those
with EDSS >5.5) would have to be established in future
research. As the instrument has not been assessed in MS
subtypes other than RRMS, PRMS, and RSPMS, it cannot be
assumed to be applicable to patients with different disease
subtypes.
In conclusion, qualitative research and psychometric vali-
dation analyses indicate that the FSIQ-RMS is fit for purpose
for measuring fatigue symptoms and impacts as a clinical
study endpoint in RMS trials. Results of the migration and
usability study confirmed the conceptual equivalence of the
FSIQ-RMS eDiary to the paper version and its appropriateness
for use with RMS patients. Responsiveness and meaningful
change, as well as variability by language version and de-
mographic subgroups (eg, sex, country), of the final FSIQ-RMS
eDiary will be analyzed in 2 international phase 3 trials of
ponesimod: OPTIMUM (ponesimod vs teriflunomide in pa-
tients with active RMS; NCT02425644) and POINT (add-on
ponesimod to dimethyl-fumarate in patients with active RMS
despite treatment with dimethyl-fumarate; NCT02907177).
First results, coming from the OPTIMUM trial, are anticipated
in 2019.
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